Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals, Inc. (DAWN)
:DAWN
Top Page
Day One Biopharmaceuticals
(NASDAQ:DAWN)
48Neutral
Positive Factors
Financial Performance
Day One increased profit in 4Q24 by decreasing their gross to net rebate from Medicaid due to Ojemda's use in pediatric disease.
Physician Adoption
Physicians are excited about the once weekly dosing regimen of Ojemda compared to daily dosing with peer drugs, leading to high rate of compliance in pediatric patients.
Product Launch
OJEMDA's launch is viewed as strong, with a +44% growth rate, supported by higher prescription volumes and improved revenue.
Negative Factors
Market Adoption
Increased treatment discontinuation rates could lead to limited market adoption post approval.
Trial Progress
New adverse events could lead to disruption in trial progress.
Day One Biopharmaceuticals (DAWN) vs. S&P 500 (SPY)
Market Cap
$817.93M
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue GrowthN/A
EPS Growth56.10%
CountryUS
Employees181
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.04
Shares Outstanding101,354,515
10 Day Avg. Volume971,804
30 Day Avg. Volume1,307,096
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.36
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.13Price Target Upside322.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Day One Biopharmaceuticals Business Overview & Revenue Model
Company DescriptionDay One Biopharmaceuticals (DAWN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. The company is dedicated to advancing innovative oncology treatments with an emphasis on improving the lives of children and adults living with cancer.
How the Company Makes MoneyDay One Biopharmaceuticals makes money primarily through the development and eventual commercialization of its oncology therapies. The company invests in research and development to create novel cancer treatments, which, upon successful clinical trials and regulatory approval, can be marketed and sold. Revenue streams include potential product sales, licensing agreements, and partnerships with larger pharmaceutical companies for the co-development or commercialization of their therapies. Additionally, Day One may secure funding through grants, collaborations, and strategic alliances that provide financial support during the clinical development stages.
Day One Biopharmaceuticals Financial Statement Overview
Summary
Day One Biopharmaceuticals demonstrates growth potential with a notable revenue increase, but consistent net losses and reliance on external financing are key challenges. While the balance sheet shows some recovery, the company must focus on achieving operational profitability and stronger cash flows to enhance financial stability.Income Statement
Day One Biopharmaceuticals has shown a significant increase in revenue in the latest year, but they still operate at a net loss, reflecting a negative net profit margin. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges in achieving profitability.45
Neutral
Balance Sheet
The company maintains a low debt-to-equity ratio, suggesting conservative leverage. However, the negative equity in previous years indicates past financial instability. Recent improvements in equity position show progress, but the equity ratio suggests a need for further strengthening.40
Negative
Cash Flow
Cash flow from operations remains negative, yet there is notable improvement in free cash flow growth. The cash flow from financing reflects reliance on external funding, which could pose risks if not managed effectively.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 131.16M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 125.88M | -383.00K | -531.00K | -199.00K | -155.00K | EBIT |
| -217.27M | -206.06M | -146.91M | -72.74M | -13.78M | EBITDA |
| -217.27M | -206.06M | -141.65M | -72.56M | -43.66M | Net Income Common Stockholders |
| -95.50M | -188.92M | -132.18M | -70.44M | -40.51M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 531.72M | 366.35M | 342.27M | 284.31M | 43.73M | Total Assets |
| 582.79M | 376.05M | 349.06M | 289.82M | 45.66M | Total Debt |
| 2.60M | 408.00K | 813.00K | 220.00K | 402.00K | Net Debt |
| -122.37M | -230.38M | -84.45M | -284.09M | -43.33M | Total Liabilities |
| 80.04M | 29.51M | 17.02M | 8.67M | 94.16M | Stockholders Equity |
| 502.75M | 346.54M | -269.67M | -127.49M | -54.20M |
| Cash Flow | Free Cash Flow | |||
| -80.28M | -150.08M | -109.90M | -56.54M | -13.58M | Operating Cash Flow |
| -78.11M | -146.85M | -109.87M | -48.54M | -13.49M | Investing Cash Flow |
| -230.99M | 128.38M | -255.07M | -8.00M | -92.00K | Financing Cash Flow |
| 203.29M | 164.00M | 165.90M | 297.12M | 29.98M |
Day One Biopharmaceuticals Technical Analysis
Negative
8.07
Price Trends
10.51
Negative
11.93
Negative
13.04
Negative
Market Momentum
-0.68
Negative
34.76
Neutral
30.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DAWN, the sentiment is Negative. The current price of 8.07 is below the 20-day moving average (MA) of 8.45, below the 50-day MA of 10.51, and below the 200-day MA of 13.04, indicating a bearish trend. The MACD of -0.68 indicates Negative momentum. The RSI at 34.76 is Neutral, neither overbought nor oversold. The STOCH value of 30.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DAWN.
Day One Biopharmaceuticals Risk Analysis
Day One Biopharmaceuticals disclosed 94 risk factors in its most recent earnings report. Day One Biopharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Day One Biopharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | $6.84B | 1.02 | -53.11% | 2.50% | 16.84% | 0.92% | |
48 Neutral | $817.93M | ― | -22.49% | ― | ― | 56.10% | |
45 Neutral | $569.32M | ― | -42.91% | ― | ― | 2.90% | |
45 Neutral | $552.62M | 55.96 | 3.73% | ― | 188.64% | ― | |
42 Neutral | $31.67M | ― | 60.38% | ― | 5.59% | 83.59% | |
38 Underperform | $34.97M | ― | -88.91% | ― | ― | 30.37% | |
29 Underperform | $74.12M | ― | -155.76% | ― | 25.77% | 32.56% |
* Healthcare Sector Average
Performance Comparison
DAWN
Day One Biopharmaceuticals
7.93
-8.23
-50.93%
FGEN
FibroGen
0.31
-2.05
-86.86%
KURA
Kura Oncology
6.60
-15.22
-69.75%
IGMS
IGM Biosciences
1.15
-8.30
-87.83%
IMTX
Immatics
4.51
-6.54
-59.19%
ALXO
ALX Oncology Holdings
0.62
-10.40
-94.37%
Day One Biopharmaceuticals Earnings Call Summary
Earnings Call Date: Feb 25, 2025 | % Change Since: -31.73% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements like the FDA approval and commercial success of OJEMDA, coupled with strong financials and strategic partnerships. However, challenges include some product discontinuations and slower adoption in certain accounts. Overall, the positives outweigh the negatives, indicating strong company momentum.Highlights
FDA Approval and Launch of OJEMDA
OJEMDA was approved by the FDA for relapsed/refractory pediatric low-grade glioma, marking a significant achievement for Day One Biopharmaceuticals and offering a new treatment option for patients.
Strong Revenue Growth
OJEMDA generated over $57 million in net product revenues in 2024, with fourth-quarter revenues reaching $29 million, representing a 44% growth compared to Q3.
Ex-U.S. Partnership with Ipsen
Day One established an exclusive licensing arrangement with Ipsen for ex-U.S. rights to OJEMDA, potentially expanding access to international markets.
Advancement of Clinical Trials
The FIREFLY-2 trial for tovorafenib is now open at over 110 sites globally, with full enrollment expected by the first half of 2026. The DAY301 program has also cleared the first dose cohort in its trial.
Strong Financial Position
Day One ended 2024 with over $500 million in cash, enabling continued investment in pipeline advancement without requiring external financing.
Lowlights
Discontinuations in Non-Promoted Uses
There were some discontinuations of OJEMDA, with 30% to 40% being for non-promoted, off-label uses, typically in faster-moving tumor types.
Moderate Adoption by Priority 2 and 3 Accounts
Despite progress, many Priority 2 and 3 accounts have not yet prescribed OJEMDA, indicating potential hesitation or slower adoption.
Non-Recurring Named Patient Program Revenue
Revenue from the named patient program, amounting to approximately $3 million in 2024, will not recur in 2025 as Ipsen assumes responsibility for these programs.
Company Guidance
During the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call, key metrics were highlighted showcasing the company's success and future plans. OJEMDA, their new pediatric low-grade glioma treatment, generated $57.2 million in net product revenues for 2024, with $29 million in the fourth quarter alone, marking a 44% increase from Q3. The company also improved its gross-to-net deductions, achieving a 12-15% forward-looking gross-to-net range after CMS granted an exclusively pediatric designation. The FIREFLY-2 trial, a Phase III study for tovorafenib, is underway with over 110 sites globally and aims for full enrollment by mid-2026. Additionally, Day One ended the year with over $500 million in cash, providing a strong financial base for continued investment in pipeline expansion and commercialization efforts.Day One Biopharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Day One Biopharmaceuticals Reports 2024 Financial Results
Positive
Feb 25, 2025
On February 25, 2025, Day One Biopharmaceuticals announced its financial results for the fourth quarter and full year 2024, reporting OJEMDA net product revenues of $29.0 million for Q4 and $57.2 million for the year. The company ended 2024 with $531.7 million in cash and investments, and highlighted the approval of OJEMDA as a catalyst for growth. Significant achievements included the Exclusively Pediatric designation for OJEMDA, progress in clinical trials, and increased R&D and SG&A expenses. The announcement reflects Day One’s strategic positioning for long-term growth and its commitment to advancing pediatric cancer treatments.
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Day One Biopharmaceuticals Reports 2024 Financial Results
Positive
Jan 13, 2025
Day One Biopharmaceuticals announced preliminary results for 2024, reporting approximately $57.2 million in net product revenue from OJEMDA, which received FDA accelerated approval. The company ended 2024 with around $531.7 million in cash and investments. In 2025, Day One plans to grow OJEMDA revenue, progress clinical trials for tovorafenib and DAY301, and maintain a strong financial position. The company also entered an exclusive licensing agreement with Ipsen for tovorafenib commercialization outside the U.S.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.